secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000950170-25-061847
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics announces FDA extends aficamten PDUFA date to Dec 26, 2025 on REMS review
--------------------------------------------------------------------------------

- FDA extended PDUFA date for aficamten NDA in oHCM to December 26, 2025, a three-month extension.
- Extension due to FDA requesting a Risk Evaluation and Mitigation Strategy (REMS) as a Major Amendment.
- No additional clinical data or studies requested; NDA originally filed without REMS.
- Cytokinetics submitted the REMS after FDA request; review continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025061847/0000950170-25-061847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025061847/cytk-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-061847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer